A blood test may rapidly distinguish brain bleeds from clot-caused strokes, even before people with stroke symptoms reach the ...

Results of multi-institutional clinical study published in peer reviewed journal 'Cancers' confirms efficacy ofOxford BioDynamics' EpiSwitch blood-based Colorectal No-Stool Test (NST) High ...

Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling ...

NEW YORK – UK-based startup Oxford Cancer Analytics is using the $11 million it has raised in a Series A financing to further develop and commercialize its protein-based lung cancer screening assay.

The global cancer diagnostics market size was valued at USD 106.32 billion in 2024 and is projected to reach from USD 112.60 ...

The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there are no biomarkers ...

Traditional approaches to prostate cancer screening involve blood tests, MRI, and biopsies. However, in addition to being ...

A test for pee-based markers of prostate cancer has previously relied on an uncomfortable first step. A new study has ...